R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.

IF 10 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL EClinicalMedicine Pub Date : 2025-01-31 eCollection Date: 2025-02-01 DOI:10.1016/j.eclinm.2025.103079
Spencer L James, Max Bourgognon, Patricia Pinto Vieira, Bruno Jolain, Sarah Bentouati, Emma Kipps, Assaf P Oron, Catherine W Gillespie, Ruma Bhagat, Altovise Ewing, Shalini Hede, Keith Dawson, Nicole Richie
{"title":"R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.","authors":"Spencer L James, Max Bourgognon, Patricia Pinto Vieira, Bruno Jolain, Sarah Bentouati, Emma Kipps, Assaf P Oron, Catherine W Gillespie, Ruma Bhagat, Altovise Ewing, Shalini Hede, Keith Dawson, Nicole Richie","doi":"10.1016/j.eclinm.2025.103079","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diversity, equity, and inclusion pertaining to race, ethnicity, and related concepts have historically been underrepresented in clinical trials for pharmaceutical drug development, although this is an increasing topic for regulators, payers, and patient advocacy groups. We aimed to develop a summary statistical measure to assess such representativeness.</p><p><strong>Methods: </strong>A statistical measure using population demographic parameters derived from performance metrics through verbal autopsy research was proposed for using population frameworks in the UK. The summary measure, R-index, was demonstrated using simulation data with population frameworks from the UK (116 Roche UK clinical trials 2013-2022) and then using published clinical trial results (NCT02366143 [March 1, 2015-September 15, 2017], NCT04368728 [July 27, 2020-October 9, 2020], and NCT04470427 [July 27, 2020-November 25, 2020]). R-index was further proposed for use with benchmarking performance in representative trial development for internal processes, external benchmarking, and performance tracking in clinical trial development.</p><p><strong>Findings: </strong>R-index was derived from a standardized statistical measure called the L1 norm, or Manhattan distance, and then normalized to the maximum theoretical error observed in some populations using population framework or ontology for reporting concepts such as race, ethnicity, and other dimensions of diversity used to characterize patient cohorts. R-index demonstrated desirable qualities in demonstration simulations, including a range of 0-1, ease of calculation and use, and interpretability and flexibility, as data standards in the space of inclusive research continue to develop.</p><p><strong>Interpretation: </strong>R-index is an interpretable, accessible summary statistic that may be useful for tracking and benchmarking representativeness in inclusive research and related domains. R-index is adaptable to different population frameworks and ontologies across different settings and considerations in terms of underlying population variables.</p><p><strong>Funding: </strong>F. Hoffmann-La Roche Ltd/Genentech, Inc.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"80 ","pages":"103079"},"PeriodicalIF":10.0000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833413/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103079","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diversity, equity, and inclusion pertaining to race, ethnicity, and related concepts have historically been underrepresented in clinical trials for pharmaceutical drug development, although this is an increasing topic for regulators, payers, and patient advocacy groups. We aimed to develop a summary statistical measure to assess such representativeness.

Methods: A statistical measure using population demographic parameters derived from performance metrics through verbal autopsy research was proposed for using population frameworks in the UK. The summary measure, R-index, was demonstrated using simulation data with population frameworks from the UK (116 Roche UK clinical trials 2013-2022) and then using published clinical trial results (NCT02366143 [March 1, 2015-September 15, 2017], NCT04368728 [July 27, 2020-October 9, 2020], and NCT04470427 [July 27, 2020-November 25, 2020]). R-index was further proposed for use with benchmarking performance in representative trial development for internal processes, external benchmarking, and performance tracking in clinical trial development.

Findings: R-index was derived from a standardized statistical measure called the L1 norm, or Manhattan distance, and then normalized to the maximum theoretical error observed in some populations using population framework or ontology for reporting concepts such as race, ethnicity, and other dimensions of diversity used to characterize patient cohorts. R-index demonstrated desirable qualities in demonstration simulations, including a range of 0-1, ease of calculation and use, and interpretability and flexibility, as data standards in the space of inclusive research continue to develop.

Interpretation: R-index is an interpretable, accessible summary statistic that may be useful for tracking and benchmarking representativeness in inclusive research and related domains. R-index is adaptable to different population frameworks and ontologies across different settings and considerations in terms of underlying population variables.

Funding: F. Hoffmann-La Roche Ltd/Genentech, Inc.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
r指数:生物制药临床试验开发中多样性、公平性和包容性的标准化代表性指标。
背景:与种族、民族和相关概念相关的多样性、公平性和包容性在药物开发的临床试验中一直未得到充分代表,尽管这是监管机构、支付方和患者倡导团体日益关注的话题。我们的目的是制定一个总结统计措施来评估这种代表性。方法:在英国提出了一种使用人口框架的统计方法,该方法使用人口统计参数,这些参数来自于通过尸检研究得出的绩效指标。综合衡量指标r指数采用英国人群框架的模拟数据(2013-2022年116项罗氏英国临床试验),然后使用已发表的临床试验结果(NCT02366143[2015年3月1日- 2017年9月15日]、NCT04368728[2020年7月27日- 10月9日]和NCT04470427[2020年7月27日- 11月25日])进行验证。R-index进一步被提议用于代表性试验开发中的基准绩效,用于内部流程、外部基准和临床试验开发中的绩效跟踪。研究结果:r指数来源于一种称为L1规范或曼哈顿距离的标准化统计度量,然后使用人口框架或本体报告概念(如种族、民族和其他用于表征患者队列的多样性维度),将其归一化为在某些人群中观察到的最大理论误差。随着包容性研究领域的数据标准不断发展,R-index在示范模拟中表现出令人满意的品质,包括0-1的范围、易于计算和使用、可解释性和灵活性。解释:R-index是一个可解释的、可访问的汇总统计数据,可能对包容性研究和相关领域的代表性进行跟踪和基准测试有用。R-index适用于不同设置和考虑潜在总体变量的不同总体框架和本体。资助:F. Hoffmann-La Roche Ltd/Genentech, Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
期刊最新文献
Cryptoglandular Anal Fistula Core Outcome Measurement Set (AFCOMS): standardised definitions and measurement instruments. Metabolic effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a prospective proof-of-concept trial. Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study. Subsequent primary cancer risks for non-hereditary colorectal cancer survivors. Association and post-iliac vein stenting symptom improvement of postural orthostatic tachycardia syndrome and orthostatic intolerance with pelvic venous disorders: two retrospective studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1